Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients. The Australian cancer-treatment company said Monday the median rate for overall ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck ...

Many Ugandans continue to face delayed diagnoses, limited access to specialised care, and low public awareness about eye ...

Experts have warned of rising cases of anal cancer across the world, which have increased by 2.9 per cent for women and 1.6 ...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head ...

Check out the latest oncology news from this week, including highlights from the 2025 American Association for Cancer Research and American Urological Association annual meetings.

This week, archaeologists identified depictions of the Milky Way galaxy in ancient Egyptian imagery. A mathematician found a ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Solid growth in diagnostics, partnerships, and therapeutic development. Revenue at $73.5M; 2025 guidance reaffirmed at $310M.

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Far from doffing their caps to actinic keratosis (AK), dermatology drug developers Almirall and Biofrontera are keeping ...